Generative engine optimization (GEO) for pharma
What generative engine optimization (GEO / AEO) means for pharma: what it is, why pharma is different, what to measure, and why it's a patient-safety signal.
A growing share of the people who once typed a drug name into Google now ask an AI instead. Patients ask ChatGPT what a diagnosis means and which treatments exist. Caregivers ask Perplexity whether a medicine is safe for an elderly parent. Clinicians ask Claude for a quick comparison between two options; payors ask about cost and evidence. In every one of those moments the AI does not return ten links to evaluate — it returns one answer. Generative engine optimization (GEO) is the work of making sure that answer is accurate, complete, and cites you.
If you have seen the term answer engine optimization (AEO), it describes the same discipline from a slightly different angle. We use GEO and AEO interchangeably. What matters is the shift underneath both words: search is becoming an answer, and pharma is largely flying blind to what that answer says.
What is generative engine optimization (GEO)?
GEO is the practice of influencing how generative AI engines describe, recommend, and cite a brand in the answers they give. It has two halves. The first is measurement — knowing, on a stable cadence, exactly what ChatGPT, Claude, Gemini, Perplexity, and Google AI Overviews say about your brand and your competitors. The second is improvement — closing the gaps between what the AI says and what is true and complete, by strengthening the sources those engines draw on.
The mechanism is different from search. In classic SEO you optimized a page to rank in a list, and the user chose. In GEO there is frequently no list — the engine synthesizes one response from the sources it trusts, and if you are not one of those sources, you are simply absent from the answer a patient reads. Being named, framed well, and cited accurately is the entire outcome.
Why GEO is different for pharma
Most GEO advice is written for consumer brands, where the worst outcome of a wrong answer is a lost sale. Pharma changes the stakes on three fronts, and any serious approach has to account for all three.
Accuracy is regulated. When an AI tells a patient your medicine treats a condition it was never approved for, understates a contraindication, or repeats an outdated label, that is not a marketing miss — it is a compliance and safety exposure with wide distribution. A generic visibility tool will report that you are named in most answers and never notice that some of those answers are wrong. In pharma, accuracy against your approved claims is the metric that matters most.
The audiences are distinct. A patient, a caregiver, a clinician, and a payor ask the same underlying question in different language and need different answers. You can be highly visible in HCP-framed answers and invisible — or wrong — in the patient-framed version of the same question. GEO for pharma has to be measured audience by audience, not as a single blended score.
Everything runs through MLR.The output of GEO in a consumer category is “publish more content.” In pharma, every asset and every correction has to be medically and legally reviewed. A credible pharma GEO program produces MLR-ready outputs and respects the promotional / non-promotional line — it does not hand a brand team a list of naive “post this everywhere” actions.
What GEO actually measures
“How visible are we in AI?” is the right instinct with the wrong shape — it is not one number. A useful GEO program scores five things on a repeated prompt set: visibility (are you named at all), share of voice (how often versus competitors), position (how prominently), sentiment (how you are framed), and accuracy (whether the statement is correct against your label and evidence). The five interact — high visibility with low accuracy is the most dangerous quadrant in pharma, maximum reach for a wrong statement — and only the combination, read by audience over time, tells you anything you can act on.
Why GEO is also a patient-safety signal, not only marketing
There is a dimension of AI monitoring that the commercial framing misses entirely. When an engine describes a medicine, it can surface adverse-event-shaped content, safety misinformation, or an off-label suggestion directly to a patient — at scale, in a channel no one is watching. That makes the AI answer surface a pharmacovigilance concern as much as a commercial one.
The point is not that a GEO platform reports adverse events — safety adjudication and reporting are, and must remain, the marketing authorization holder's process. The point is that continuous monitoring gives medical and safety teams early sight of what patients are actually being told, so that a finding which warrants review reaches the right team quickly rather than surfacing weeks later through another channel. It is why we are extending percivo's monitoring toward structured detection of adverse-event-shaped content — detected and routed to your PV team to assess, never a substitute for your safety processes. Any pharma leader evaluating a GEO tool should ask how it treats safety-relevant content, not only competitive share of voice.
How to start
Begin with measurement, not action. Fix a prompt set that mirrors how your real audiences ask — patient, caregiver, clinician, payor — run it across the engines on a stable cadence, and score all five metrics with accuracy checked against your approved claims. That baseline tells you where you are absent, where you are named but wrong, and where a competitor is quietly owning the answer. Only then does improvement have a target: strengthen the authoritative, well-structured, frequently-cited sources the engines draw on, take corrections through MLR, and re-measure to prove the fix held.
Common questions
What is generative engine optimization (GEO)?
Generative engine optimization (GEO) is the practice of shaping how AI answer engines — ChatGPT, Claude, Gemini, Perplexity, Google AI Overviews — describe and cite a brand when someone asks them a question. Where SEO optimized a page to rank in a list of blue links, GEO influences the single synthesized answer the AI gives. It is the same discipline many people call answer engine optimization (AEO); the terms are used interchangeably.
How is GEO different for pharma?
Three ways. First, accuracy is regulated: an AI statement that contradicts the label, overstates efficacy, or implies an off-label use is a compliance and safety issue, not just a marketing miss. Second, the audiences are distinct — patients, caregivers, clinicians, and payors ask the same question in very different language and need different answers. Third, anything you publish or ask a third party to change runs through MLR. Generic GEO tools measure visibility; pharma GEO has to measure whether the answer is correct against your approved claims.
Is GEO the same as SEO?
No. SEO gets a page ranked so a person can click it; GEO shapes the answer the AI gives before anyone clicks anything. They share inputs — authoritative, well-structured, frequently-cited content helps both — but the outcome is different. In AI answers there is often no list to rank in, just one response, and being the source it draws on is the whole game.
How do you measure GEO for a pharma brand?
On a fixed prompt set and a repeated cadence, score every AI answer on five things: whether the brand is named (visibility), how often versus competitors (share of voice), how prominently (position), how it is framed (sentiment), and whether the statement is correct against approved claims (accuracy). Split all five by audience. Accuracy is the metric most tools skip and the one that matters most in a regulated category.
Why does AI monitoring matter for patient safety, not just marketing?
Because when an AI describes a medicine, it can surface adverse-event-shaped content, safety misinformation, or an off-label suggestion directly to a patient. That makes the AI answer surface a pharmacovigilance concern as well as a commercial one. Continuous monitoring gives medical and safety teams early sight of what patients are being told, so anything that warrants review reaches the right team quickly.
Whether you call it GEO or AEO, the underlying reality is the same: AI is becoming the front door to medical information, and for most pharma brands the answer behind that door is unmonitored. Measuring it — accurately, by audience, with safety in view — is the first move. See how percivo.ai approaches it.